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AbsTrACT
Constitutional pathogenic variants in TP53 are 
associated with Li- Fraumeni syndrome or the more 
recently described heritable TP53- related cancer 
syndrome and are associated with increased lifetime 
risks of a wide spectrum of cancers. Due to the broad 
tumour spectrum, surveillance for this patient group 
has been limited. to date, the only recommendation 
in the UK has been for annual breast mRi in women; 
however, more recently, a more intensive surveillance 
protocol including whole- body mRi (WB- mRi) has 
been recommended by international expert Groups. to 
address the gap in surveillance for this patient group 
in the UK, the UK Cancer Genetics Group facilitated a 
1- day consensus meeting to discuss a protocol for the 
UK. Using a preworkshop survey followed by structured 
discussion on the day, we achieved consensus for a UK 
surveillance protocol for TP53 carriers to be adopted by 
UK Clinical Genetics services. the key recommendations 
are for annual WB- mRi and dedicated brain mRi from 
birth, annual breast mRi from 20 years in women and 
three- four monthly abdominal ultrasound in children 
along with review in a dedicated clinic.
bACkground
Li- Fraumeni syndrome (LFS) is a rare inherited cancer 
predisposition syndrome, first described by Frederick 
Li and Joseph Fraumeni in 1969.1 LFS is caused by 
pathogenic variants (PVs) in the TP53 gene.2 Indi-
viduals with LFS have a very substantially increased 
lifetime risk of cancer, with risks reported to be as 
high as 22% by 5 years of age, 41% by 18 years of 
age and approaching 100% by 70 years of age.3 4 
The most frequent cancers that occur in patients with 
LFS are bone and soft tissue sarcomas, very early- 
onset breast cancer, malignant tumours of the central 
nervous system and adrenocortical cancers (ACCs). 
However, of note, with expanded testing of cancer 
predisposition genes outside the context of a strong 
family history of cancer and identification of TP53 
PVs in population databases, there is widening recog-
nition that the phenotypical spectrum and cancer risk 
for individuals with a constitutional TP53 PV may be 
both broader and lower than initially described.5–7 
This has led to recent suggestions to expand the clin-
ical description of constitutional TP53 PVs from LFS 
to a wider cancer predisposition syndrome designated 
heritable TP53- related cancer syndrome (hTP53rc) 
(GD Evans from GENTURIS expert group, personal 
communication).
Most TP53 carriers in the UK have been identified 
through referral to clinical genetics services due to 
a strong personal or family history of cancer, where 
genetic testing has largely been recommended on 
clinical criteria such as the ‘Chompret criteria’.3 Once 
a PV has been identified within a family, predictive 
genetic testing can be offered to at- risk relatives.
There has been a long- standing hesitancy to offer 
genetic testing of TP53 due to the absence of surveil-
lance recommendations should a TP53 PV be identi-
fied. To date, the only nationally agreed surveillance 
recommendation for individuals with a TP53 PV 
has been for breast surveillance with annual breast 
MRI from age 20 in women.8 However, over the 
past 5 years, recommendations for more compre-
hensive surveillance for TP53 carriers have been 
made, most notably the Toronto protocol, an inten-
sive protocol involving clinical, biochemical and 
radiological surveillance that has demonstrated a 
survival benefit.9 10 One of the unique aspects of this 
protocol is the use of whole- body MRI (WB- MRI). 
WB- MRI has been separately studied in a number of 
centres across North America, Canada and Europe, 
and a meta- analysis of the data from 13 studies in 
578 TP53 carriers from six countries, including the 
UK SIGNIFY study, evidences a 7% (95% CI 5% to 
9%) new cancer detection rate, with the majority of 
cancers being detected at a sufficiently early stage to 
allow treatment with curative intent.11 12
In 2017, an expert international group published 
recommendations on surveillance for individuals 
with LFS.13 This publication necessitated a review 
of current UK practice. Therefore, the UK Cancer 
Genetics Group (UKCGG), with support from the 
George Pantziarka TP53 Trust (the UK LFS patient 
advocacy group), organised a national consensus 
meeting on 6 July 2018 to agree on a consistent 
approach to the management of TP53 carriers across 
the UK.
MeThods
Pre-meeting preparation
Preparation for the meeting included a systematic 
review of the literature to identify key publications 
on surveillance in LFS to inform discussion. As there 
is limited literature available on this topic, only five 
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key publications were selected for discussion at the meeting: 
publications relating to the Toronto protocol, recent Interna-
tional Recommendations, results of a meta- analysis of baseline 
WB- MRI and results from a UK study of WB- MRI.9 11–13
Prior to the meeting, these publications and a survey (online 
supplementary information 1) were sent out to the 24 UK 
Regional Genetics centres. This approach has been successful 
for other UKCGG guidelines.14 The survey focused on ques-
tions relating to current practice and sought opinion on the 
surveillance recommendations made by the International TP53 
Consensus Group.13 The response rate to the survey was 22/24 
(91.7%). The themes arising from the survey were then used to 
create a series of key questions to be addressed at the consensus 
meeting.
Consensus group participants
Forty- three stakeholders attended from across the UK and 
Ireland, including patient support group representatives (n=3), 
clinical cancer geneticists (n=19), genetic counsellors (n=6), 
paediatric oncologists (n=2), oncologists (n=3), radiologists 
(n=8), psychologists (n=1) and pathologists (n=1). Each of the 
24 UK genetics centres was represented.
Presentation of current knowledge
The first part of the meeting was structured into a series of talks. 
The talks covered the history of LFS and TP53 the associated 
cancer risks, surveillance suggested by other expert groups, a UK 
perspective on WB- MRI and the survey results. These lectures 
provided a review of the available evidence and equipped the 
Consensus Group, who were from a variety of backgrounds 
with up- to- date evidence on which to base their recommen-
dations. The agenda and presentations from the day are avail-
able online https://www. ukcgg. org/ information- education/ 
ukcgg- consensus- meetings/
discussion groups
The group was then divided into three small working groups to 
discuss three key questions listed as follows. Participants in each 
group were selected to include a range of the multidisciplinary 
team. Each group had a nominated facilitator and scribe. After 
each discussion, there was feedback and discussion and debate by 
the wider group until a consensus was reached. Once all delegates 
had discussed the three key questions, the final part of the day was 
a group forum to agree on a UK surveillance protocol.
Meeting report
Following the meeting, the agreed statements were circulated to 
the group and presented at the UK- CGG Winter Meeting 2018 
for further comments to ensure that the statements were an accu-
rate representation of the day and consensus had been reached. 
A summary of the meeting was posted on the UKCGG website 
in March 2019 (https://www. ukcgg. org/ information- education/ 
ukcgg- consensus- meetings/).
resulTs
Pre-meeting survey
Most centres who responded to the survey (17/22) were not 
currently offering any surveillance other than the recommended 
annual breast MRI from age 20 years, which was available by 
direct referral to the NHS Breast Screening Programme. Four 
centres were offering adrenal ultrasound (US) in children, and 
three centres were able to offer WB- MRI or were in the process 
of trying to set this up.
With regard to opinion on the International Consensus guide-
lines, the main themes that arose from survey respondents were 
either disagreement or concern with specific areas of the guide-
lines and/or the implementation of any agreed recommenda-
tions within the NHS. Specifically, there was concern about the 
requirement for general anaesthetic for WB- MRI in childhood 
and uncertainty about the requirement for brain MRI, in addi-
tion to WB- MRI and the use of gadolinium in imaging. There 
was also strong disagreement with the recommendation for 
upper gastrointestinal (GI) endoscopy and lower GI colonos-
copy. More general comments were the lack of clinical evidence 
for benefit of early detection on long- term outcome of patients 
and concern over the high false- positive rate of WB- MRI.
Regarding implementation of any guidelines, survey respon-
dents wanted to address who should be responsible for coordi-
nating surveillance and whether this should be undertaken in all 
centres or in specialist clinics. The change in practice towards 
offering predictive testing in childhood if surveillance was avail-
able was also discussed.
The results and questions raised by the survey were then split 
into three main themes to be discussed on the day.
Question 1: what surveillance should we recommend?
The group reviewed the International Consensus recommenda-
tions based on the Toronto Protocol.13 For the majority of the 
recommendations, consensus was reached that we should adopt 
the same recommendations. However, there was further discus-
sion of a number of key areas; clinical breast examination, US of 
the abdomen and pelvis in adults, upper and lower GI endoscopy 
and annual dermatological examination.
Clinical breast examination has not been proven to be an 
effective screening tool,15 and the Department of Health issued 
advice that clinical breast examination was not an appropriate 
screening technique in February 1998 (PL/CMO/98/1). Instead 
the recommendation of the Consensus Group would be to 
ensure that women are educated in breast self- examination and 
to recommend annual breast MRI surveillance, and the option of 
risk- reducing mastectomy was discussed.
With regard to abdominal US in adults, it was not felt that US 
would offer additional benefit over WB- MRI in adults, partic-
ularly as the incidence of ACC in adults is low. In the Toronto 
study, while US in childhood was found to be beneficial, abdom-
inal and pelvic US did not detect any cancers in adults.9
Consensus was reached not to offer surveillance of the upper 
GI tract. The main reason for this decision is that current data 
suggest that only a small number of TP53 carriers develop an 
upper GI malignancy. Recent data suggest that 2% of TP53 
carriers develop stomach cancer and 0.6% develop oesophageal 
cancer.3 This risk is comparable to the general population risk of 
developing gastric cancer from birth to age 74 of 1.87% in men 
and 0.79% in women worldwide.16 Upper GI endoscopy is also 
not recommended in the Toronto protocol, and there is limited 
evidence to suggest that it results in any survival benefit.17 
Although there is no specific data relating to Helicobacter pylori 
(HP) eradication in TP53 carriers, it is recognised that HP is 
a risk factor for gastric cancer and evidence that eradication 
reduces gastric cancer risk.18 Therefore, the group felt that 
advice on testing and eradication of HP should be specifically 
recommended, as well as more general advice not to smoke.
Consensus was reached not to offer surveillance of the lower 
GI tract. Colorectal cancer has been postulated to be associated 
with LFS; however, review of the relevant literature provides 
little supporting evidence for this. Sixteen cases of colorectal 
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Table 1 Agreed surveillance recommendations for TP53 carriers
Tumour screening recommendation
ACC Abdominal USS 3–4 monthly birth:18 years
Biochemistry (17 OH- progesterone, total testosterone, DHEAS, androstenedione) should only be performed where there is an unsatisfactory USS.
Breast cancer
(women only)
Annual dedicated MRI from age 20–70 years
Consider risk- reducing mastectomy from age 20 years
Brain tumour Annual dedicated brain MRI from birth (first MRI with contrast)*
Sarcoma Annual WB- MRI† from birth*
Haematological Routine FBC are not indicated due to lack of evidence that these detect haematological malignancy at an early stage.
Colon Colonoscopy only indicated when family history of colorectal cancer or polyposis‡; consider investigation for, possibly coinherited, causes if strong family 
history of colorectal cancer or polyposis
The presence of microcytic anaemia should prompt investigation for a gastrointestinal tract malignancy (routine FBC not advised).
Gastric Recommend Helicobacter pylori testing and eradication if required
Endoscopy not indicated due to lack of evidence
Skin Annual dermatology review from 18 years (general practitioner or dermatology)
General advice on use of high protection factor sunscreen and covering up in sun
Physical examination Full physical examination 3–4 monthly in children (including blood pressure, anthropometric measurements, signs of virilisation and neurological exam)
Routine physical examination not recommended in adults; advise detailed discussion of ‘red flag’ symptoms and low threshold for fast track referral of 
persistent or unusual symptoms
Other Recommend detailed discussion of red flag symptoms in both children and adults and provide information on relevant resources.
Discuss importance of making positive lifestyle choices (eg, not smoking, eating a healthy diet, limiting alcohol consumption, sun protection, keeping 
physically active and providing appropriate resources).
Notes: (1) Currently on most scanners, arms are not covered adequately, and these should be evaluated clinically; (2) patients to be recalled for detailed imaging to evaluate 
uncertain lesions; (3) units wanting to do WB- MRI have to opt in (ie, self- certify quality for WB- MRI); (4) a minimum number of scans per year in a unit have not been specified; 
(5) optional sequences can be performed at the discretion of the unit; (5) radiology should be informed of any current clinical symptoms to inform interpretation of scan.
*Children weighing less than 20 kg need sedation, examination without anaesthetic may be possible from the age of 5 years with help from a dedicated play specialist. Feed and 
wrap approach may also be possible in the first year.
†Recommended core minimum sequence for WB- MRI (adults): T1, T2 fat sat/STIR or diffusion and non- fat sat T2; images can be acquired in axial or coronal planes or mixture; 
slice thickness (including gap) not greater than 10 mm; coverage vertex to feet; optional sequences at the discretion of the unit. Radiology should be informed of any current 
clinical symptoms to inform interpretation of scan.
‡For individuals with a family history of colorectal cancer, we would suggest reference to the recently published British Society of Gastroenterology/Association of 
Coloproctologists of Great Britain and Ireland/United Kingdom Cancer Genetics Group guidelines for hereditary colorectal cancer.21
FBC, full blood count.
cancer were reported in a series of 397 patients with cancer from 
64 families with LFS, giving a similar risk to general population 
risk (4%), although admittedly at younger ages.19 Of note, many 
of the patients with colorectal cancer were not proven TP53 
carriers. Another study reported 6/497 TP53 carriers in a series 
of patients with colorectal cancer at age 40 years or younger, 
but evaluation of the identified variants showed that only 1/6 
variants would be classified as likely pathogenic or pathogenic 
based on current guidelines.20 Therefore, the opinion of the 
Consensus Group is that there is no sufficient evidence that 
colorectal cancer risk is increased in LFS and that colonoscopic 
surveillance should only be considered if there is a family history 
of colorectal tumours according to recently published guidelines 
and investigation for other inherited causes of colorectal cancer 
if appropriate.21
Regarding annual dermatological review, the group recognised 
the resource implications for this, and it was felt that this could 
be undertaken by the patient’s general practitioner with a low 
threshold for referral to dermatology.
The Consensus Group also felt that it was important to 
ensure there was detailed discussion of ‘red flag’ symptoms in 
both children and adults and provide information on relevant 
resources and to discuss the importance of making positive life-
style choices, for example, not smoking, eating a healthy diet 
and being physically active.
The concern raised through the premeeting survey regarding 
the requirement for general anaesthetic for WB- MRI in child-
hood was also discussed. Data on cancer risk were reviewed, and 
it was strongly felt that due to the high risks of cancer reported in 
infancy,3 general anaesthetic was acceptable in order to provide 
the appropriate surveillance. This position was supported by the 
patient advocates present at the meeting.
The group also discussed the requirement for dedicated brain 
MRI. Malignant tumours of the central nervous system are a 
core cancer in LFS. The meta- analysis of WB- MRI compared 
the outcomes of WB- MRI with dedicated brain MRI and 
demonstrated that of 10 brain tumours identified in individuals 
having both WB- MRI and brain MRI, 5 tumours were missed 
by WB- MRI.12 The Consensus Group therefore agreed that 
both dedicated brain MRI and WB- MRI should be included in 
the surveillance protocol. The use of gadolinium was felt to be 
necessary for the first but not subsequent scans.
The surveillance protocol agreed by the Consensus Group is 
detailed in table 1.
Question 2: who should we offer surveillance to?
TP53 PVs are identified in approximately 30% patients fulfilling 
Chompret criteria and up to 75% of patients with classic LFS.3 
This discussion focused on whether we would offer surveillance 
only to patients with confirmed PVs in TP53, those who meet 
clinical criteria for LFS but do not have a confirmed TP53 PV or 
those with PVs predicted to be of lower penetrance for example, 
the Brazilian founder PV c.1010G>A, p.ArgR337His. In addi-
tion, we also considered the situation of patients who are at 
50% risk of a familial TP53 PV but do not wish to proceed with 
predictive testing.
The Consensus Group felt that for patients with classic 
LFS but without a confirmed TP53 PV, surveillance should be 
offered for patients affected with a relevant cancer. It was felt 
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box 1 eligibility for surveillance
The aforementioned screening programme should be offered to
 ► Patients with a TP53 PV (class 4 or 5 according to American 
College of Medical Genetics ACMG guidelines).
 ► Patients with constitutional (germline) mosaicism for a TP53 
PV (verified by confirmation in two tissues).
 ► Patients with low- penetrance TP53 PVs, until further data on 
cancer risk available.
 ► Patients affected with cancer fulfilling classic Li- Fraumeni 
syndrome (LFS) criteria#* without a pathogenic TP53 variant 
(confirmation of cancer diagnoses required).
The above screening programme should not be offered to
 ► Patients at 50% risk of familial TP53 PV. Patients at 50% risk 
should have appropriate counselling and support but should 
be encouraged to consider testing in order to access cancer 
screening.
 ► Paediatric patients at 50% risk of familial TP53 PV should 
continue to be offered support and review in a specialist 
clinic, but screening is not appropriate unless they are 
confirmed to have inherited the familial PV.
 ► Adult patients at 50% risk.*†
*Classic LFS criteria=proband with a sarcoma diagnosed before age 45 
years and a first- degree relative with any cancer before age 45 years and 
a first- degree or second- degree relative with any cancer before age 45 
years or a sarcoma at any age.
†Women at 50% risk of a TP53 PV can be offered annual breast MRI 
from age 20 years.
that Li- Fraumeni- like (LFL) criteria had largely been designed 
to broaden the clinical criteria and increase sensitivity for 
testing of TP53. Therefore, for LFL families without a TP53 
PV, the lifetime risks of cancer were unlikely to be in the range 
of that observed for classic LFS and surveillance of this patient 
group was not supported. With regards to lower- penetrance 
variants, it was felt that at present without the benefit of clear 
genotype phenotype correlations, the surveillance protocol 
should be offered to all patients with a TP53 PV, recognising 
that more reliable phenotype–genotype data may lead to 
genotype- specific modifications of these recommendations in 
the future.
Offering the full surveillance protocol for those at 50% risk 
was not considered appropriate due to the intensity of the 
surveillance protocol. However, women at 50% of a TP53 PV 
can still be offered breast MRI in line with National Institute 
for Clinical Excellence (NICE) guidelines.8 Children at 50% risk 
should be reviewed in a specialist clinic, ideally with a paediatric 
oncologist and clinical geneticist, to discuss the surveillance and 
testing, red flag symptoms. If predictive testing is not pursued 
open access back to the clinic should be offered for when the 
family wish to pursue testing or if they have further questions.
The Consensus Group noted that the recommendation of 
a surveillance protocol will likely change both clinician and 
patients’ perspectives of having a genetic test for TP53 and also 
that it would be appropriate to offer predictive testing in child-
hood for a familial PV.
The recommendations for who should be offered surveillance 
are set out in box 1.
Patients with an LFL family history. Screening should be 
offered on the basis of cancer in the family according to other 
recommended guidelines, for example, breast cancer.
Question 3: where should surveillance be offered?
It was felt by the Consensus Group that due to the expertise 
required in surveillance and assessment of symptoms in child-
hood that coordination of screening in children should managed 
through specialist paediatric oncology clinics.
For adults, the opinion was that coordination of screening 
should ideally be through clinical genetics services, provided 
appropriate resources where in place.
It was recognised that the ability to offer surveillance to unaf-
fected TP53 carriers in a non- oncology setting would be prefer-
able but not always possible due to local arrangements.
Overall, the opinion was that a small number of national 
specialist clinics would be best placed to manage this work and 
prospectively audit the surveillance protocol. However, it was 
recognised that the funding of such a service may be difficult.
It was agreed that WB- MRI should only be undertaken where 
there is sufficient radiology expertise to report the imaging and 
that local clinical genetics centres should consider referral for 
WB- MRI to another centre if their local department were unable 
to work to the radiology working group standards (table 1 
footnote).
disCussion
This is the first UK clinical guideline for the surveillance and 
management of TP53 carriers. The strength of the guidance is 
that opinion was sought prior to the meeting to identify key 
areas of discussion, and the Consensus Group was formed from 
a broad range of medical specialties and patient advocates who 
were given equal voice during discussion. The different perspec-
tives and expertise of the group enriched the discussion and 
allowed the group to achieve a consensus view.
Our key recommendations are that a UK surveillance protocol 
based on international guidelines should be offered to TP53 
carriers from birth. The major limitation of the guidelines is the 
lack of robust evidence on which to base our discussions and 
recommendations. However, it was recognised that due to the 
rarity of LFS and TP53 PVs, there is, and likely always will be, 
a limited evidence base to support screening recommendations 
in terms of early detection and cancer mortality. It is, therefore, 
recommended that discussion of the screening recommendations 
with patients should include a thorough discussion of the pros 
and cons of screening, consideration of the family history of 
cancer and that future screening recommendations may change 
as more data become available, particularly with respect to 
surveillance for specific variants. It is also recommended that 
screening data are prospectively collected and audited to inform 
future practice and fill gaps in our understanding.
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